US court denies Amgen appeal over Pfizer biosimilar

A US federal court has rejected Amgen’s appeal in a patent infringement case related to Pfizer’s biosimilar version of protein-based anaemia drug Epogen (epoetin alfa). Amgen was trying to overturn a lower court decision denying its request to force Pfizer to turn over additional details about its rival product, which would assist Amgen’s patent defence.